MeiraGTx to earn up to $415 million in Janssen deal

21 December 2023
meiragtx_large

Shares in gene therapy company MeiraGTx (Nasdaq: MGTX) shot up by around 20% in Thursday morning’s trading in New York.

The firm earlier announced an asset purchase agreement with the Johnson & Johnson (NYSE: JNJ) subsidiary Janssen, in which it exchanged future potential royalties for its Phase III candidate, botaretigene sparoparvovec, for a total of up to $415 million.

Under the terms of the deal, MeiraGTx is eligible to receive $130 million in upfront and near-term milestone payments, as well as an additional $285 million if the drug reaches commercialization.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology